Lunesta Crossover Trial Design, Unblinding By Taste Raised As Review Issues
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA should re-consider its preference for parallel group rather than crossover trial designs in sleep drug development programs, according to FDA Office of Drug Evaluation I Director Robert Temple, MD